local_hospital

Klinički bolnički centar Rijeka (Clinical Hospital Center Rijeka)

Address
Kresimirova 42, 51000 Rijeka, Croatia

Klinički bolnički centar Rijeka - Neurology and Epilepsy Research

The Clinical Hospital Center Rijeka (Klinički bolnički centar Rijeka) is a leading medical institution in Croatia actively engaged in advanced neurological research. The center demonstrates particular expertise in investigating novel therapeutic approaches for patients with complex and difficult-to-treat neurological conditions.

  • Refractory focal onset epilepsy treatment optimization
  • Adjunctive antiepileptic therapy evaluation
  • Novel pharmacological interventions for treatment-resistant seizure disorders

The center's research portfolio emphasizes improving outcomes for patients with refractory epilepsy, focusing on evaluating innovative compounds that offer hope to individuals who have not responded to standard antiepileptic medications. Through participation in international clinical trials, the institution contributes to advancing the understanding of seizure reduction strategies and the development of new treatment options for patients with focal onset epilepsy who face limited therapeutic alternatives.

Site Overview

assignment
54
connected trials
corporate_fare
33
sponsors
science
149
IMPs

Activity Indicator

Last 6 months

4
Trials started
-33% vs previous period.
6
Trials started 6–12 months ago
54
Total trials linked
Highly Active
trending_downDeclining-33%
1
1
1
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 15 therapeutic areas and 15 of 149 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 147 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
24
Sponsors (total)
33
Active sponsors
19

Sponsor Network

Top 19 by active trials.

lock +18 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +7 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 60 other sites in Croatia

description
Trial volume
54
Outperforms 93% of sites
public
Therapeutic diversity
15areas
Outperforms 93% of sites
groups
Sponsor diversity
33sponsors
Outperforms 92% of sites

Therapeutic Area Benchmark — Croatia

Select a therapeutic area to compare against other sites in Croatia.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Croatia

Market Share

Country: Croatia

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Klinički bolnički centar Rijeka (Clinical Hospital Center Rijeka)

lock Showing 1 of 54 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.Celltrion Inc.Phase IIINot RecruitingJan 2024

IMP list

lock Showing 1 of 149 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Epcoritamab3Unknown2023-01-262024-09-03

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.